April 8 (Reuters) - Jupiter Neurosciences Inc JUNS.O:
JUPITER NEUROSCIENCES INC - DOES NOT ANTICIPATE IMPACT FROM U.S. TARIFFS ON CLINICAL-STAGE PRESCRIPTION PRODUCT DEVELOPMENT
JUPITER NEUROSCIENCES: TO INITIATE JNS115 PARKINSON’S PHASE 2A TRIAL IN Q3 2025
Source text: ID:nGNX5LXb8C
Further company coverage: JUNS.O
((Reuters.Briefs@thomsonreuters.com;))